Selegiline
Mostrando 1-10 de 10 artigos, teses e dissertações.
-
1. AVALIAÇÃO DO ENVOLVIMENTO DA ENZIMA MONOAMINA OXIDASE B EM MODELOS DE DOR PÓS-OPERATÓRIA E NEUROPÁTICA EM CAMUNDONGOS / ASSESSMENT OF MONOAMINE OXIDASE B INVOLVEMENT ON MODELS OF POSTOPERATIVE AND NEUROPATHIC PAIN IN MICE
As monoaminas possuem uma função modulatória importante nas vias descendentes do controle da dor e estão envolvidas no mecanismo antinociceptivo de diversos fármacos comumente utilizados no tratamento de síndromes dolorosas. Nesse estudo, nós avaliamos a participação da monoamina oxidase B (MAO-B), uma enzima chave envolvida no metabolismo das monoa
Publicado em: 2010
-
2. Influências de um inibidor seletivo da monoamino-oxidase tipo-B (IMAO-B) na sensibilização comportamental para anfetamina em camundongos / Influences of a selective inhibitor monoamine oxidase type-B (IMAO-B) in behavior sensitization for amphetamine in mice.
A sensibilização comportamental é caracterizada por aumento no efeito comportamental de uma droga após administrações repetidas. Este fenômeno é intensamente aplicado em estudos com modelos animais que enfocam a dependência de drogas. A maioria destas drogas promove adaptações em sistemas de neurotransmissão, (ex. sistema dopaminérgico), como é
Publicado em: 2006
-
3. Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells
Increased dopamine catabolism may be associated with oxidative stress and neuronal cell death in Parkinson's disease. The present study was carried out to examine the effect of dopamine on the expression of heme oxygenase-1 and -2 (HO-1 and HO-2) in human neuroblastomas (SK-N-SH cell line) and the effects of selegiline and antioxidants on this expression. Ce
Brazilian Journal of Medical and Biological Research. Publicado em: 2004-07
-
4. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.
The deprenyl and tocopherol antioxidative treatment (DATATOP) study has shown that selegiline (deprenyl), with or without tocopherol, reduces physical and psychological deficits in patients with Parkinson's disease within one month of treatment and reduces the probability of reaching a primary endpoint, the decision to treat with levodopa. This paper critica
-
5. Investigation by Parkinson’s Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry
Objective: To determine whether the excess mortality observed in patients who received both levodopa and selegiline in a randomised trial could be explained by revised diagnosis of Parkinson’s disease, autonomic or cardiovascular effects, more rapid disease progression, or drug interactions.
British Medical Journal.
-
6. Selegiline (Eldepryl) for Parkinson's disease.
-
7. Selegiline shortage: Causes and costs of a generic drug shortage
American Academy of Neurology.
-
8. Mortality in people taking selegiline: observational study
Objective: To evaluate mortality among patients with Parkinson’s disease receiving different treatment.
British Medical Journal.
-
9. The on-off phenomenon.
The on-off phenomenon is an almost invariable consequence of sustained levodopa treatment in patients with Parkinson's disease. Phases of immobility and incapacity associated with depression alternate with jubilant thaws. Both pharmacokinetic and pharmacodynamic factors are involved in its pathogenesis, but evidence is presented to indicate that the importan
-
10. Treatment of Parkinson's disease.
Pharmacotherapy with levodopa for Parkinson's disease provides symptomatic benefit, but fluctuations in (or loss of) response may eventually occur. Dopamine agonists are also helpful and, when taken with low doses of levodopa, often provide sustained benefit with fewer side effects; novel agonists and new methods for their administration are therefore under